Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc announces it purchased 2,062,463 ordinary shares of
Haleon plc reports the purchase and cancellation of 2,191,437 ordinary shares of each as part of the second tranche of its buyback programme announced 31 July 2025.
Trades executed on 28 August 2025 totalled 2,191,437 shares at prices reported on the London Stock Exchange/CBOE (UK)/CXE with an average indicative price shown in the announcement. After settlement, registered share capital is 8,961,283,874 ordinary shares, with 3,880,205 held in treasury, leaving 8,957,403,669 ordinary shares carrying voting rights. The company provides a link to a full breakdown of individual trades and notes the announcement is not an offer for securities. More details are available on the company website.
Haleon plc announces it purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,963,475,311 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,959,595,106 ordinary shares with voting rights. A full breakdown of the individual trades is provided via the linked RNS PDF and will also be available on the Company's investor website. The announcement clarifies it does not constitute an offer for securities.
Haleon plc announced the purchase and cancellation of 2,975,063 ordinary shares of each under the second tranche of its buyback programme announced 31 July 2025. The trades were executed on 26-27 August 2025 on the London Stock Exchange CBOE (UK)/CXE with individual trade prices reported and a weighted figure of 359.1984 shown in the announcement. After settlement the company's registered share capital is 8,966,351,142 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,962,470,937 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown and to the company's investor website for details.
Haleon plc announced the purchase and cancellation of 1,369,903 ordinary shares under the second tranche of its share buyback programme. The trades were executed on the London Stock Exchange/CBOE (UK)/CXE on 22 August 2025 and a full breakdown of individual trades is linked in the release. After settlement, the company's registered share capital is 8,969,326,205 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares, leaving 8,965,446,000 ordinary shares with voting rights. The announcement clarifies where the trade details and the announcement are available online.
Haleon plc announced the purchase and cancellation of 175,642 ordinary shares of of each as part of the second tranche of its share buyback programme announced on 31 July 2025. After settlement, Haleon registered share capital stands at 8,970,696,108 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,966,815,903 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the Company's investor website. This announcement relates solely to the executed tranche of the buyback programme and the resulting share capital figures.
Haleon plc announced the purchase and cancellation of 930,345 ordinary shares under the second tranche of its buyback programme. Reported trade prices ranged between £360.90 and £367.00 with a reported volume-weighted average price of £363.4411. After settlement the company states its registered share capital is 8,970,871,750 ordinary shares, of which 3,880,205 are held as treasury, leaving 8,966,991,545 ordinary shares with voting rights. The announcement points shareholders to a full trade breakdown and notes the release does not constitute an offer for securities.
Haleon plc filed a Form 6-K publishing a TR-1 notification showing major holdings in the Company. The notice reports 423,379,327 direct voting rights (4.72%) and additional financial instruments totaling 26,420,926 voting rights plus equity swaps of 193,460 rights, amounting to 5.01% of voting rights through financial instruments. The disclosure identifies Wellington Management Group LLP and related controlled undertakings as the reporting chain that holds the 5.01% position. The TR-1 was published around 19-20 August 2025 and includes nominee holdings and a full chain of controlled undertakings for the reporting entity.
Haleon plc reports the purchase and cancellation of 1,504,400 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 18 August 2025 via London Stock Exchange CBOE (UK)/CXE at an average price of 358.0459 per share. After settlement, registered share capital is 8,971,802,095 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,967,921,890 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc reports the purchase and cancellation of 1,600,000 ordinary shares of £0.01 each as part of the second tranche of its buyback programme announced 31 July 2025. After settlement, registered share capital is 8,973,306,495 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,969,426,290 voting ordinary shares. A full breakdown of individual trades is available via the provided RNS link and on the Company website. The announcement states it does not constitute an offer for securities.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
